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Biotransformation enzymes 
in development of renal injury 
and urothelial cancer caused by 
aristolochic acid
M Stiborová1, E Frei2 and HH Schmeiser2
Ingestion of aristolochic acid (AA) is associated with the development 
of AA-nephropathy and Balkan endemic nephropathy, which are 
characterized by chronic renal failure, tubulointerstitial fibrosis, and 
urothelial cancer.  Understanding which enzymes are involved in AA 
activation and/or detoxification is important in assessing susceptibility 
to AA. Xiao et al. demonstrate that hepatic cytochrome P450s in mice 
detoxicate AA and thereby protect kidney from injury. The relative 
contribution of enzymes activating AA to induce urothelial cancer in 
humans remains to be resolved.
Kidney International (2008) 73, 1209–1211. doi:10.1038/ki.2008.125
1Department of Biochemistry, Faculty of Science, 
Charles University, Prague, Czech Republic; and 
2Division of Molecular Toxicology, German Cancer 
Research Center, Heidelberg, Germany
Correspondence: M Stiborová, Department 
of Biochemistry, Faculty of Science, Charles 
University, Albertov 2030, 128 40 Prague 2, Czech 
Republic.  
E-mail: stiborov@natur.cuni.cz
The paper by Xiao et al.1 (this issue) 
addresses the interesting and still unset-
tled question of whether the metabolism 
of aristolochic acid (AA) determines 
its pathophysiological effects, and, if 
so, which enzymes participating in this 
process are responsible. AA, a naturally 
occurring nephrotoxin and carcinogen, is 
associated with urothelial cancer develop-
ment in patients suﬀering from Chinese 
herb nephropathy, now termed aristolo-
chic acid nephropathy (AAN), and may 
also be a cause of the development of a 
similar type of kidney ﬁbrosis with malig-
nant transformation of the urothelium, 
Balkan endemic nephropathy (BEN).2,3 
The molecular mechanisms for AA-medi-
ated renal injury, and whether it is an early 
stage of the urothelial-specific tumor 
development, are still matters of debate 
and need further investigations. In this 
context, it is noteworthy that a case of AA-
induced tumor development without renal 
injury4 suggests dissociation between 
AA-mediated nephrotoxicity and carci-
nogenicity. AA seems to directly cause 
renal injury by activating mitochondrial 
permeability transition, which was found 
recently in human renal tubular epithe-
lial cells,5 and metabolic activation of AA 
to species forming DNA adducts is an 
important step for AA-induced malignant 
transformation.3,6 Indeed, the molecular 
mechanism of AA-induced carcinogen-
esis demonstrates a strong association 
between DNA adduct formation, muta-
tion pattern, and tumor development.3 
The predominant AA-DNA adduct, 7-
(deoxyadenosin-N6-yl) aristolactam I 
(dA-AAI), which is the most persistent of 
the adducts in the target tissue, is a muta-
genic lesion leading to A→T transversions 
in the p53 gene in DNA from urothelial 
tumors of AAN and BEN patients.3,7
One of the common features of AAN 
and BEN is that not all individuals 
exposed to AA suﬀer from nephropa-
thy and tumor development. We have 
suggested earlier that one cause of 
these diﬀerent responses may be indi-
vidual diﬀerences in the activities of the 
enzymes catalyzing the biotransforma-
tion (detoxication and/or activation) 
of AA (for a summary, see Stiborová et 
al.6). Many genes of enzymes metabo-
lizing toxicants and carcinogens are 
known to exist in variant forms or show 
polymorphisms resulting in diﬀering 
activities of the gene products. These 
genetic variations appear to be impor-
tant determinants of cancer risk or other 
toxic eﬀects of xenobiotics.6
The proposed activation and detoxica-
tion pathways for the major component of 
AA, aristolochic acid I (AAI), are shown 
in Figure 1. AAI is activated by simple 
nitroreduction to N-hydroxyaristolactam 
I, which forms a cyclic N-acylnitrenium 
ion as the ultimate carcinogenic species 
binding to DNA. The most important 
human and rat enzyme activating AAI 
in vitro is hepatic and renal cytosolic 
NAD(P)H:quinone oxidoreductase 
(NQO1), followed by hepatic microsomal 
cytochrome P450 (CYP) 1A1/2 and renal 
microsomal NADPH:CYP reductase 
(CPR), besides prostaglandin H synthase 
(cyclooxygenase (COX)), which is highly 
expressed in urothelial tissue.6 It is of note 
that NQO1 polymorphism (the geno-
type NQO1*2/*2) was found to predis-
pose patients suﬀering from BEN to the 
development of urothelial malignancy of 
the upper urinary tract (odds ratio 13.75, 
95% conﬁdence interval 1.17–166.21).8 
This ﬁnding, together with the demon-
stration of the importance of NQO1 in 
AAI activation, could be an explanation 
for cancer induction by AAI in only some 
of the AAN and BEN patients.
The competing conversion of N-
hydroxyaristolactam I to the correspond-
ing 7-hydroxyaristolactam or its further 
reduction to aristolactam I should be 
considered a detoxication pathway; 
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both these metabolites were found to be 
excreted. However, even though aristol-
actam I is not a direct DNA-binding spe-
cies, low amounts of the dA-AAI adduct, 
with the highest levels in one of the target 
tissues, the renal pelvis, were generated in 
rats treated with aristolactam I.9 This result 
is consistent with the ﬁnding of formation 
of the dA-AAI adduct by aristolactam I 
after its in vitro activation with diﬀerent 
peroxidases, of which several, such as 
COX-1 and/or COX-2, are expressed at 
high levels in renal tissue. It is still ques-
tionable whether enzymes capable of 
conjugating the proximate carcinogenic 
metabolite of AAI, N-hydroxyaristol-
actam I, are involved in AAI activation. 
Meinl et al.10 demonstrated that expres-
sion of some human sulfotransferases 
(SULTs), particularly SULT1A1, in bacte-
rial and mammalian target cells enhances 
the mutagenic activity of AAI. Moreover, 
an increase in AAI-induced mutagenic-
ity was correlated with higher AAI-DNA 
adduct levels in V79 cells transfected with 
human SULT1A1.6 However, an increase 
in AAI-DNA adduct levels was found nei-
ther in human hepatic and renal cytosols, 
to which the SULT cofactor was added, nor 
in an in vitro system consisting of human 
NQO1 and SULT1A1.6
Although the enzymes catalyzing the 
reductive activation of AAI in vitro have 
already been identiﬁed, the question of 
which of them actually participates in this 
process in vivo remains to be answered. 
Additional factors such as route of admin-
istration, absorption, renal clearance, and 
tissue-speciﬁc enzyme expression make it 
diﬃcult to extrapolate from data found in 
vitro6 to the in vivo situation.
In contrast to the enzymes activat-
ing AAI in vitro, those participating 
in AAI detoxication both in vitro and 
in vivo had not been investigated until 
the study of Xiao et al.1 Hepatic cyto-
chrome P450 reductase-null (HRN) 
mice, which we had shown previously 
to be a suitable model to determine 
hepatic xenobiotic metabolism in vivo11 
and had suggested for use to elucidate 
AA metabolism,6 were successfully 
used in their interesting study.1 The 
authors’ novel results clearly indicate 
that hepatic CYPs detoxify AAI by its 
demethylation to aristolochic acid Ia 
(AAIa) and thereby protect the kid-
ney from AAI-induced injury.1 AAIa 
or its conjugates the O-glucuronide, 
O-acetate, and O-sulfate esters were 
excreted in urine. AAIa is also reduced 
to N-hydroxyaristolactam Ia, forming 
aristolactam Ia, which together with its 
conjugates, the N- and O-glucuronides, 
is excreted.6 Enzymatic reactions lead-
ing to aristolactam Ia and its metabolites 
seem to be purely a detoxication path-
way, as DNA adducts containing aristol-
actam Ia structure have as yet not been 
found. The observations of Xiao et al.,1 
combined with results found previously, 
support strongly the former hypothesis6 
that a key point determining the carcino-
genic and nephrotoxic eﬀects of AAI lies 
in the balance of activities of reductases 
such as NQO1, catalyzing the AAI-DNA 
adduct formation, and enzymes such as 
CYPs, which detoxicate AAI to AAIa.
Figure 1 | Proposed pathway for metabolic activation and detoxication of aristolochic acid I (AAI), leading to renal injury and urothelial 
cancer. AAN, aristolochic acid nephropathy; BEN, Balkan endemic nephropathy; COX, cyclooxygenase; CPR, NADPH:CYP reductase; CYP, cytochrome 
P450; dA-AAI, 7-(deoxyadenosin-N6-yl)aristolactam I; NQO1, NAD(P)H:quinone oxidoreductase; SULT, sulfotransferase.
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The question of which of the CYP 
enzymes are responsible for formation of 
AAIa remains still to be investigated. The 
in vitro experiments of Xiao et al.1 indicate 
that CYP1A generates AAIa. However, 
the model used to evaluate CYP1A par-
ticipation in formation of AAIa in vivo, 
mice treated with an inducer of CYP1A 
3-methycholanthrene (MC), did not bring 
unambiguous results. Namely, MC also 
induces other enzymes besides CYP1A. 
Although treatment of mice with MC 
leads to a decrease in AAI concentrations 
in the liver and kidney, an increase in 
AAIa concentrations was found not in the 
liver but only in the kidney of mice treated 
with the higher dose of AAI (20 mg/kg). 
An increase in excretion of AAIa due to 
its conjugation with glucuronide, caused 
by induction of UDP-glucuronosyltrans-
ferase with MC, could occur. Nevertheless, 
because CYP1A enzymes also activate 
AAI to species forming DNA adducts,6 the 
decrease of AAI in liver and kidney might 
also result from this reaction. Moreover, 
NQO1, which is also eﬃciently induced 
by MC, could contribute to decreased AAI 
levels in MC-treated mice.
Taking into account all data known 
at the present time, we propose that the 
pathways of AAI metabolism are dictated 
by the binding aﬃnity of AAI to CYP1A 
or NQO1, and their enzymatic turnover, 
as well as by the balance of the eﬃciency 
of CYP1A at oxidizing versus reducing 
AAI. In order to conﬁrm this assumption 
and to complement the work of Xiao et 
al.,1 we have started a study investigat-
ing formation of AAI-DNA adducts in 
the HRN mouse model and in models in 
which CYP1A genes are deleted.
Although the impact of individual 
enzymes that metabolize AAI on its 
nephrotoxicity and carcinogenicity in vivo 
is still not entirely resolved, one question 
was unambiguously answered by Xiao et 
al.:1 hepatic CYP enzymes detoxicate AAI 
in mice, thus decreasing its renal toxicity. 
The evaluation of interindividual vari-
ations in the human enzymes playing a 
major role in AAI activation and detoxi-
cation, including their genetic polymor-
phisms, remains a major challenge to 
explain an individual’s susceptibility to 
AAI and to predict cancer risk among 
AAN and BEN patients.
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Plasma exchange for myeloma 
kidney: cast(s) away?
WF Clark1 and AX Garg1,2
Leung et al. (this issue) present a retrospective study of 40 patients. 
Observations in 14/40 led to the suggestion of restitution of plasma 
exchange for light-chain responsive, biopsy-proven myeloma kidney 
until a better randomized control trial (RCT) is constructed. A careful 
analysis of their study and a recent RCT suggest little difference in 
outcome between plasma exchange and control groups. The analysis 
supports restitution of a better RCT of plasma exchange for myeloma 
kidney rather than off-label use.  
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Acute kidney injury in the setting of mul-
tiple myeloma has a strong impact on 
patient morbidity, mortality, health-care 
utilization, and cost.1–4 A unique and 
important cause of acute kidney injury 
in multiple myeloma is cast nephropathy, 
in which renal inﬂammation results from 
an excess of filtered monoclonal light 
chains that are transported to the inter-
stitium of the kidney via speciﬁc recep-
tors in the proximal tubule. The receptors 
become overloaded by the light chains, 
which then combine with Tamm-Horsfall 
protein, forming obstructive casts in the 
renal tubules.5 Plasma exchange has been 
shown to remove light chains transiently 
and may have an adjunctive eﬀect when 
combined with eﬀective chemotherapy 
in the treatment of cast nephropathy.3,6,7 
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